✓ verbatim from the press
Brazil's Unified Health System (SUS) will replace the 10-valent pneumococcal conjugate vaccine (PCV10) with the 20-valent version (PCV20) starting in June, doubling the prevented serotypes against pneumococcal disease. The Health Ministry published a preliminary technical guide on Wednesday (27) orienting health professionals about the change, according to reports from O Tempo and TVT News outlets. ✓
Press quotes (2)
"O Sistema Único de Saúde (SUS) vai começar a oferecer, a partir de junho, um imunizante mais abrangente contra a doença pneumocócica. A vacina pneumocócica conjugada 20-valente (VPC20 ou Pneumo 20) vai substituir a 10-valente, dobrando os sorotipos prevenidos"
"O Ministério da Saúde publicou nesta quarta-feira (27) um guia técnico preliminar com orientações sobre a mudança para profissionais de saúde"
The decision is justified by the increase in pneumococcal meningitis cases in children under 5 years old in recent years. From 2013 to 2019, Brazil registered an average of 164 annual cases in this age group, but from 2022 to 2024 the average rose to 211.3 cases, according to Health Ministry surveillance data cited by the outlets. ✓
Press quotes (1)
"De 2013 a 2019, o Brasil registrou uma média de 164 casos anuais de meningite pneumocócica em crianças de até 5 anos. De 2022 a 2024, a média anual subiu para 211,3 casos"
According to Flávia Bravo, director of the Brazilian Society of Immunizations, the increase reflects an epidemiological phenomenon called "replacement," where other bacterial serotypes gain ground when types covered by the previous vaccine are controlled. Ministry data shows that almost 40% of severe cases between 2018 and 2023 were caused by just two bacterial types not prevented by PCV10, but included in the new PCV20. ✓
Press quotes (2)
"A introdução da vacina 10-valente foi excelente na redução desses dez tipos, o que representou uma queda importante nas doenças graves. Mas o pneumococo tem uma característica que a gente chama de "replacement": você controlando um tipo, reduzindo a circulação, outro tipo pode começar a ganhar o espaço"
"Dados da vigilância do Ministério da Saúde mostram que quase 40% dos casos graves com amostra coletada entre 2018 e 2023 foram causados por apenas dois tipos da bactéria não prevenidos pela VPC10, mas incluídos na formulação da VPC20"
During the transition, children will receive the 20-valent vaccine in the first dose and booster, maintaining the 10-valent only in the second dose. The new vaccine will also replace the PCV13 and PPV23 currently offered to high-risk groups after existing stocks are depleted. ✓
Press quotes (2)
"Durante o período de transição da VPC10 para a VPC20, as crianças receberão a vacina 20-valente na primeira dose e no reforço, e a 10-valente na segunda dose"
"O Programa Nacional de Imunizações já oferece outras vacinas mais abrangentes contra a doença pneumocócica, a VPC13 e a VPP23, mas apenas para públicos específicos, com determinadas condições de saúde que aumentam a vulnerabilidade às formas graves da doença. Esses imunizantes também serão substituídos pela VPC20 após o fim dos estoques"
Covered by only some sources, or where the accounts diverge.
Covered by only some sources (1)
PCV10 reduced 60% of meningococcal disease cases and 65% of pneumococcal meningitis cases since 2010
-
What is the specific legal basis authorizing the vaccine replacement in SUS?
Why it's still unknown: Consulted outlets did not identify the ordinance, resolution or normative act that formalizes the change, only mentioning a 'preliminary technical guide'
-
What is the comparative cost between PCV10 and PCV20 and the budgetary impact of the change?
Why it's still unknown: No outlet reported the vaccine acquisition values or additional cost estimate for the system
-
What is the specific distribution timeline of the new vaccine across states?
Why it's still unknown: The report indicates only that 'municipalities will be able to start applying the vaccine as soon as they receive the immunizer', without logistical detail
-
Who is the PCV20 supplier and what volume of doses was acquired?
Why it's still unknown: Outlets did not identify the supplier laboratory or the volume contracted for national implementation